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Hypothesis 
Recombinant activated factor VIIa (rFVIIa) can effectively 
reduce hematoma growth and improve outcomes when 
given within 4 hours of symptom onset in patients with acute 
intracerebral hemorrhage. 
Methods 
Design: International multi-center randomized placebo-
controlled trial. 
Setting: Emergency departments and intensive care units 
in 73 hospitals in 20 countries. 
Subjects: 399 adults age 18 years or older with 
spontaneous intracerebral hemorrhage documented by CT 
scanning within 3 hours of onset of symptoms. Exclusion 
criteria included a score of 3 to 5 on the Glasgow Coma 
Scale (indicating deep coma); planned surgical evacuation 
of hematoma within 24 hours after admission; secondary 
intracerebral hemorrhage related to aneurysm, 
arteriovenous malformation, trauma, or other causes; known 
use of oral anticoagulant agents; known thrombocytopenia; 
history of coagulopathy, acute sepsis, crush injury, or 
disseminated intravascular coagulation; pregnancy; 
preexisting disability; and symptomatic thrombotic or vaso-
occlusive disease within 30 days before the onset of 
symptoms of intracerebral hemorrhage. Midway through the 
trial, the last criterion was amended to exclude patients with 
any history of thrombotic or vaso-occlusive disease.
Intervention: Patients were randomly assigned to receive a 
single intravenous dose of 40 µg, 80 µg, or 160 µg per 
kilogram of rFVIIa (NovoSeven, Novo Nordisk) or placebo. 
Treatment was given within one hour after the baseline CT 
and no later than four hours the symptom onset. 
Outcomes: The primary outcome was percent change in 
volume of intracerebral hemorrhage at 24 hours. Secondary 
outcomes included 90-day mortality and functional status. 
Results 
Hematoma volume increased more in the placebo group 
than in the rFVIIa groups. The mean increase was 29 
percent in the placebo group, as compared with 16 percent, 
14 percent, and 11 percent in the groups given 40 µg, 80 
µg, and 160 µg of rFVIIa per kilogram, respectively (P=0.01 
for the comparison of the three rFVIIa groups with the 
placebo group). Growth in the volume of intracerebral 
hemorrhage was reduced by 3.3 ml, 4.5 ml, and 5.8 ml in 
the three treatment groups, as compared with that in the 
placebo group (P=0.01). At 90 days, 69% percent of 
placebo-treated patients died or were severely disabled (as 
defined by a modified Rankin Scale score of 4 to 6), as 
compared with 55 percent, 49 percent, and 54 percent of 
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respectively (P=0.004 for the comparison of the three rFVIIa 
groups with the placebo group). Mortality at 90 days was 29 
percent for patients who received placebo, as compared 
with 18 percent in the three rFVIIa groups combined 
(P=0.02). Serious thromboembolic adverse events, mainly 
myocardial or cerebral infarction, occurred in 7 percent of 
rFVIIa-treated patients, as compared with 2 percent of those 
given placebo (P=0.12). 
Conclusion 
Treatment with rFVIIa within four hours after the onset of 
intracerebral hemorrhage limits the growth of the 
hematoma, reduces mortality, and improves functional 
outcomes at 90 days, despite a small increase in the 
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Commentary 
Intracerebral hemorrhage (ICH) is a devastating form of 
acute stroke; only 38% of affected patients surviving the first 
year [2]. Those that do survive are likely to be functionally 
impaired. The size of the hematoma is directly related to 
outcome [3] and measures that have the potential to reduce 
hematoma growth, typically due to early rebleeding, may 
reduce morbidity and mortality. rFVIIa is approved for the 
treatment of bleeding in patients with hemophilia and it has 
been reported to reduce perioperative blood loss after major 
surgery in subjects without coagulopathy [4]. The current 
study by Mayer et al. [1] represents the first evidence that 
rFVIIa may also be helpful for patients with ICH. 
This was a well-designed, phase IIb, international, multi-
center, randomized placebo-controlled trial that evaluated 
escalating doses of rFVIIa given within four hours of primary 
intracranial hemorrhage. Not only was early hematoma 
growth reduced in the group treated with rFVIIa, but long-
term (90-day) clinical outcomes, including mortality and 
functional status, were also significantly improved.  
The potential implications of this study for patients with ICH 
are enormous, yet a few limitations deserve consideration. 
The trial was relatively small (n=399). Though patients were 
randomly allocated to the two treatment groups, there were 
some baseline differences between the arms of the trial, 
such as more brainstem hemorrhages in the placebo group, 
which could have biased the results in favor of rFVIIA. While 
not significantly different, there were greater numbers of 
thrombotic events (7% vs. 2%, P=0.12) in those randomized 
to rFVIIa, a finding that is not surprising considering the 
drug’s mechanism of action. In fact, exclusion criteria were 
amended midway through the trial to exclude subjects with 
any history, as opposed to a history within the prior 30 days, 
of thrombotic or vaso-occlusive disease. The results of this 
study only apply to the treatment of primary ICH, which is 
due to spontaneous rupture of small vessels in the setting of 
chronic hypertension or amyloid angiopathy [2]. Whether the 
benefits extend to patients with secondary ICH, typically due 
to anticoagulation, vascular abnormalities, trauma, or 
tumors, remains to be seen. 
A phase III trial of rFVIIa designed to address many of these 
issues is currently underway [5]. This study will enroll 675 
patients with primary ICH within 3 hours of symptom onset, 
with the primary goal of reducing disability and improving 
clinical outcome after 3 months. The neurological critical 
care community will anxiously await the results of the trial. 
Until then, clinicians and pharmacy and therapeutics 
committees will struggle to balance the potential benefits, 
harm, and expense of this drug. 
Recommendation 
Until the results of the phase III trial are available, we 
cannot recommend widespread use of rFVIIa for the 
treatment of primary ICH. Should individual clinicians chose 
rFVIIa in this setting, its use should be restricted to those 
patients meeting entry criteria, including timeframe, of the 
Mayer et al. study [1]. 
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